• Hepatitis C is a contagious liver disease that impairs the organ’s ability to remove toxins from the body. The Hepatitis C virus (HCV) is spread through contact with the blood of an infected person. Before 1992, Hepatitis C was commonly caused by blood transfusions and organ transplants. More recently, sharing needles, obtaining tattoos with unsterile tools, or rarely, partaking in unprotected sex with an infected person, contributes to the spread HCV.
    • The disease can either be acute, lasting only a few weeks, or chronic, developing into a serious, lifelong illness. An estimated 75-85% of all infected individuals will develop chronic infection.


    • Most people display no symptoms of a result of Hepatitis C infection. However, symptoms that may present are fever, fatigue, loss of appetite, nausea/vomiting, abdominal pain, dark urine, clay-colored bowel movements, joint pain and yellowing of the skin and eyes.
    • HCV causes liver damage regardless of the presence of symptoms. Right quadrant pain and tenderness, bleeding or bruising, ascites, itchy skin, mental fogginess, and insulin resistance or Type 2 Diabetes are potential indications of liver damage.


    • Hepatitis C treatment currently includes the use of oral combination direct-acting antiviral (DAA) agents.
    • Therapeutic regimens are tailored to a patient’s baseline characteristics including genotype, previous treatment history, viral load, degree of liver fibrosis and comorbid conditions.
    • Current treatment modalities allow for sustained virologic response (SVR) or cure of the viral infection. However, viral eradication does not protect against re-infection.